Cargando…

Primary chemotherapy for operable breast cancer: the NSABP experience

Detalles Bibliográficos
Autor principal:	Bear, HD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231901/ http://dx.doi.org/10.1186/bcr1221

Ejemplares similares

Sentinel node biopsy versus conventional axillary dissection in clinically node-negative breast cancer patients
por: Bear, HD
Publicado: (2005)

Adjuvant chemotherapy for operable breast cancer: old vs new schema
por: Valagussa, P, et al.
Publicado: (2005)

Minimal residual disease (MRD) in the bone marrow in ER-α-positive primary breast cancer patients
por: Coombes, RC, et al.
Publicado: (2005)

Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)
por: Nieto, Y
Publicado: (2005)

SOLTI (Solid Tumor Intensification) Group experience with high-dose chemotherapy treatment for early breast carcinoma
por: Funes, H Cortés, et al.
Publicado: (2005)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

Surgical management of women with screen-detected breast cancer: preoperative factors indicating risk of multiple operations versus a single operation in women undergoing surgery for screen detected breast cancer
por: Currie, RJ, et al.
Publicado: (2009)

Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy
por: Roy, R, et al.
Publicado: (2010)

Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer
por: Pusztai, L
Publicado: (2011)

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
por: Advani, Pooja P., et al.
Publicado: (2023)

Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30
por: Henry, N. Lynn, et al.
Publicado: (2022)

Ultrasound and fine needle aspiration assessment of the axilla in patients with operable invasive breast cancer
por: Stewart, VR, et al.
Publicado: (2006)

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab
por: Ganz, Patricia A., et al.
Publicado: (2021)

The sialyl-glycolipid SSEA4 marks a subpopulation of chemotherapy resistant breast cancer cells with mesenchymal features
por: Aloia, Andrea, et al.
Publicado: (2015)

Evaluating tumour response to primary radiochemotherapy in breast cancer patients: what role for breast magnetic resonance imaging?
por: Thibault, F, et al.
Publicado: (2008)

Parallel testing of several genes (panel-testing) in patients with ectodermal dysplasia using next-generation sequencing
por: Gabriel, HD, et al.
Publicado: (2012)

Size matters: second breast cancer size following treatment for primary cancer as a predictor of survival
por: MacLennan, GS, et al.
Publicado: (2010)

Automated breast volume scanner: an initial experience
por: Hughes, EK, et al.
Publicado: (2011)

Evaluation of three APBI techniques under NSABP B‐39 guidelines
por: Scanderbeg, Daniel, et al.
Publicado: (2009)

Apoptotic chemotherapies
por: Pardee, AB, et al.
Publicado: (2005)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2019)

Breast clinic referrals – should mastalgia be managed in primary care?
por: Alamiri, Jamal, et al.
Publicado: (2013)

Translational breast cancer research in luminal breast cancer
por: Dowsett, M
Publicado: (2011)

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients
por: Page, David B, et al.
Publicado: (2015)

Feasibility of surgeon performing ultrasound in symptomatic breast clinics: the Brighton experience
por: Rathinaezhil, RS, et al.
Publicado: (2006)

How can you survive a cardiac operation after cardiac operation? (analysis of pre- and postoperative data of redone cardiac operations)
por: Vaszily, M, et al.
Publicado: (2013)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
por: Jacobs, Samuel A., et al.
Publicado: (2020)

Epigenetics of breast cancer
por: Esteller, M
Publicado: (2011)

Stem cells in normal breast development and breast cancer
por: Wicha, MS, et al.
Publicado: (2003)

Long-term survival of interval breast cancers in breast cancer screening in Wales
por: Fong, YF, et al.
Publicado: (2012)

Changes On Mean Systemic Filling Pressure And Microcirculation After a Fluid Challenge
por: Aya, HD, et al.
Publicado: (2015)

Could additional operational fund improve the performance of health centres' underfunded public health programmes? Learning from the Sleman district experience
por: Krisnaeni, Novita
Publicado: (2014)

Targeting the right chemotherapy for the right patient
por: Conte, PF, et al.
Publicado: (2005)

The future of breast cancer prevention
por: Howell, A, et al.
Publicado: (2005)

Genomic profiling of breast cancer
por: Borg, Å
Publicado: (2005)

Update on breast cancer genetics
por: Izatt, L
Publicado: (2006)

Clinical breast cancer and estrogen
por: Chew, HK
Publicado: (2003)

Predictive factors in breast cancer
por: Klijn, J, et al.
Publicado: (2000)

Immunity and autoimmunity in breast cancer
por: Curigliano, G
Publicado: (2011)

Comparison between pre-operative MRI and intra-operative endoscopic findings for idiopathic normal pressure hydrocephalus
por: Kita, Daisuke, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_blnd9tb0eikn4jeirc57e2bq6m